The B And T Lymphocyte Attenuator pipeline drugs market research report outlays comprehensive information on the B And T Lymphocyte Attenuator targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the B And T Lymphocyte Attenuator pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Immunology, Oncology, and Dermatology which include the indications Graft Versus Host Disease (GVHD), Autoimmune Disorders, Solid Tumor, Renal Cell Carcinoma, and Atopic Dermatitis (Atopic Eczema). It also reviews key players involved in B And T Lymphocyte Attenuator targeted therapeutics development with respective active and dormant or discontinued products.

The B And T Lymphocyte Attenuator pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 1, 1, 2, and 2 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.

B And T Lymphocyte Attenuator overview

B- and T-lymphocyte Associated is a protein that in humans is encoded by a gene BTLA. It is also known as cluster of differentiation 272 or CD272 and belongs to the CD28 immunoglobulin superfamily (IgSF). It contains a single immunoglobulin (Ig) domain and is a receptor that relays inhibitory signals to suppress the immune response.

For a complete picture of B And T Lymphocyte Attenuator’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.